PT2160221E - Péptidos cíclicos antagonistas de cxcr4 - Google Patents

Péptidos cíclicos antagonistas de cxcr4 Download PDF

Info

Publication number
PT2160221E
PT2160221E PT08769524T PT08769524T PT2160221E PT 2160221 E PT2160221 E PT 2160221E PT 08769524 T PT08769524 T PT 08769524T PT 08769524 T PT08769524 T PT 08769524T PT 2160221 E PT2160221 E PT 2160221E
Authority
PT
Portugal
Prior art keywords
cyclic peptide
cxcr4 antagonists
peptide cxcr4
antagonists
cyclic
Prior art date
Application number
PT08769524T
Other languages
English (en)
Portuguese (pt)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2160221(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2160221E publication Critical patent/PT2160221E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT08769524T 2007-05-30 2008-05-20 Péptidos cíclicos antagonistas de cxcr4 PT2160221E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
PT2160221E true PT2160221E (pt) 2011-09-12

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08769524T PT2160221E (pt) 2007-05-30 2008-05-20 Péptidos cíclicos antagonistas de cxcr4

Country Status (32)

Country Link
US (3) US7691813B2 (OSRAM)
EP (2) EP2160221B1 (OSRAM)
JP (1) JP5358564B2 (OSRAM)
KR (2) KR101319740B1 (OSRAM)
CN (1) CN101678213B (OSRAM)
AR (1) AR066648A1 (OSRAM)
AT (1) ATE516853T1 (OSRAM)
AU (1) AU2008260326B2 (OSRAM)
BR (1) BRPI0812134A2 (OSRAM)
CA (1) CA2688574C (OSRAM)
CL (1) CL2008001467A1 (OSRAM)
CO (1) CO6241137A2 (OSRAM)
CR (1) CR11105A (OSRAM)
CY (1) CY1111815T1 (OSRAM)
DK (1) DK2160221T3 (OSRAM)
DO (1) DOP2009000270A (OSRAM)
EA (1) EA017716B1 (OSRAM)
GT (1) GT200900304A (OSRAM)
HR (1) HRP20110551T1 (OSRAM)
IL (1) IL201685A (OSRAM)
JO (1) JO2776B1 (OSRAM)
MA (1) MA31666B1 (OSRAM)
MX (1) MX2009012952A (OSRAM)
MY (1) MY149432A (OSRAM)
NZ (1) NZ580849A (OSRAM)
PE (1) PE20090299A1 (OSRAM)
PL (1) PL2160221T3 (OSRAM)
PT (1) PT2160221E (OSRAM)
TN (1) TN2009000496A1 (OSRAM)
TW (1) TWI423987B (OSRAM)
WO (1) WO2008150689A1 (OSRAM)
ZA (1) ZA200908345B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
WO2012168336A1 (en) * 2011-06-07 2012-12-13 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
KR20200043970A (ko) * 2017-09-05 2020-04-28 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
WO2019126796A1 (en) * 2017-12-21 2019-06-27 Mainline Biosciences Llc Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US11639373B2 (en) 2018-09-12 2023-05-02 Technische Universität München Therapeutic and diagnostic agents for cancer
CA3108450A1 (en) 2018-09-12 2020-03-19 Technische Universitat Munchen Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
JP7541532B2 (ja) * 2019-04-18 2024-08-28 プロビンシャル・ヘルス・サービシーズ・オーソリティ 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
TW202235429A (zh) * 2020-12-25 2022-09-16 日商中外製藥股份有限公司 含ｎ－置換－胺基酸殘基之胜肽化合物的製備方法
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
CN119325480A (zh) * 2022-04-20 2025-01-17 省卫生服务机构 靶向cxcr4的化合物及其制备和使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
CA2643744A1 (en) * 2006-02-27 2007-08-30 Technische Universitaet Muenchen Cancer imaging and treatment

Also Published As

Publication number Publication date
KR20100003737A (ko) 2010-01-11
HRP20110551T1 (hr) 2011-09-30
CA2688574C (en) 2014-02-18
JP2010529957A (ja) 2010-09-02
PE20090299A1 (es) 2009-03-19
BRPI0812134A2 (pt) 2014-11-18
EA017716B1 (ru) 2013-02-28
KR101319740B1 (ko) 2013-10-17
AU2008260326A1 (en) 2008-12-11
EP2160221A1 (en) 2010-03-10
NZ580849A (en) 2012-03-30
MA31666B1 (fr) 2010-09-01
EP2377579A1 (en) 2011-10-19
JO2776B1 (en) 2014-03-15
WO2008150689A1 (en) 2008-12-11
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
AU2008260326B2 (en) 2011-07-21
EP2160221B1 (en) 2011-07-20
TN2009000496A1 (en) 2011-03-31
USRE42274E1 (en) 2011-04-05
TWI423987B (zh) 2014-01-21
CL2008001467A1 (es) 2008-12-05
IL201685A0 (en) 2010-05-31
JP5358564B2 (ja) 2013-12-04
CN101678213A (zh) 2010-03-24
MY149432A (en) 2013-08-30
CN101678213B (zh) 2013-11-06
GT200900304A (es) 2011-11-09
CR11105A (es) 2010-04-12
AR066648A1 (es) 2009-09-02
HK1141474A1 (en) 2010-11-12
KR101169846B1 (ko) 2012-08-01
PL2160221T3 (pl) 2011-12-30
CY1111815T1 (el) 2015-10-07
DK2160221T3 (da) 2011-09-19
US20100130409A1 (en) 2010-05-27
CO6241137A2 (es) 2011-01-20
DOP2009000270A (es) 2010-01-15
IL201685A (en) 2015-04-30
EA200971129A1 (ru) 2010-04-30
US7691813B2 (en) 2010-04-06
ATE516853T1 (de) 2011-08-15
TW200902556A (en) 2009-01-16
US20080300177A1 (en) 2008-12-04
MX2009012952A (es) 2009-12-11
CA2688574A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
IL201685A0 (en) Cyclic peptide cxcr4 antagonists
IL213676A0 (en) C5ar antagonists
DK3275894T3 (en) Antagonistisk cxc-chemokin-receptor-4(cxcr4)-polypeptid
ZA201000776B (en) Cyclic depsipeptides
IL219046A (en) Kntc2 peptide derivatives
IL210506A0 (en) Complement antagonists and uses thereof
ZA200906812B (en) Crig antagonists
EP2167112A4 (en) CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
SG10201608071YA (en) Biologically active peptides
EP2483300A4 (en) SYNTHETIC PEPTIDE ANTAGONISTS OF MYOSTATIN
IL201485A0 (en) New cyclic peptide compounds
ZA201000283B (en) Reinigung pegylierter polypeptide
GB0723712D0 (en) Peptides
IL193427A0 (en) Polypeptide antagonist
GB201000798D0 (en) Poly-TLR antagonists
ZA201202150B (en) [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
GB0703945D0 (en) Peptide
SI2160221T1 (sl) Antagonisti cikličnih peptidov cxcr4
GB0708529D0 (en) Peptide standards
PL2195338T3 (pl) Interferon alfa zmodyfikowany na końcu N
IL207264A0 (en) Bonbesin analog peptide antagonist conjugates
EP2351771A4 (en) IMMUNOSUPPRESSIVE PEPTIDE
GB0705115D0 (en) Peptides
GB0705251D0 (en) Peptides
GB0810553D0 (en) Peptide analogues and conjugates thereof